Conclusion. Ceftobiprole is a novel, broad-spectrum, parenteral cephalosporin undergoing Phase III clinical trials. Its broad spectrum of activity makes it a candidate for monotherapy of cSSSIs ...

and specific broad-spectrum antibiotics known to contribute most to antibiotic resistance (co-amoxiclav, quinolones, and cephalosporins). Secondly, a fixed amount of tax per unit of the drug.

Clinical outcomes among adult inpatients were no worse when broad-spectrum antibiotic therapy was delayed vs started early, challenging the belief that overly broad-spectrum empiric antibiotic ...

Credit: Getty Images. Ceftobiprole is a broad spectrum cephalosporin antibiotic. The Food and Drug Administration (FDA) has accepted the New Drug Application for ceftobiprole, an investigational ...

Patients were excluded if they had a history of an allergic reaction with or an intolerability to either cephalosporins or vancomycin, severe renal dysfunction (CL cr of <30 mL/min), hepatic ...